TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00321100
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
Study: NCT02674737
Drug: tramadol and flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00603980
Drug: Inhaled placebo + oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato placebo + oral placebo
Study: NCT00603980
Drug: Oral placebo qualifying session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qualifying control session (oral placebo)
Study: NCT00218036
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
Study: NCT04507438
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet administered daily for an 8 week period
Study: NCT00654511
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 1mcg/kg, Intravenous (IV)
Study: NCT00654511
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 2mcg/kg, Intravenous (IV)
Study: NCT00115804
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
Study: NCT01683071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 20 mL as single-injection femoral nerve block prior to total knee arthroplasty
Study: NCT03260205
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
Study: NCT01893242
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to aleglitazar, once a day for approximately 3 years
Study: NCT00649649
Drug: Accupril® Tablets 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg, single dose fed
Study: NCT03629418
Drug: Targeted blood-pressure management
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic norepinephrine infusion is started before anesthetic induction and maintained throughout surgery. The target is to maintain systolic blood pressure at 110 mmHg or higher.
Study: NCT03629418
Drug: Routine blood-pressure management
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (25-50 ug) is injected or vasopressors is infused only when necessary. The target is to maintain systolic blood pressure at 90 mmHg or higher during surgery.
Study: NCT01793051
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
Study: NCT01972880
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT04534439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of APX-115-matching placebo 400mg capsule once daily for 12 weeks
Study: NCT03226080
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline will be administered as a placebo in equal volume for the placebo group
Study: NCT04439838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02854137
Drug: BAY987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
Study: NCT02523313
Drug: Double Placebo Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
Study: NCT01830543
Drug: vitamin K antagonist (VKA)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
Study: NCT04433169
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy
Study: NCT00625365
Drug: DEFINITY®
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
Study: NCT00000513
Drug: chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02955134
Drug: Chinese medicine prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.~Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
Study: NCT02955134
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
Study: NCT00262080
Drug: Phosphate Buffer Saline (PBS),
Approvals — FDA: no, EMA: no, PMDA: no
Description: given as three 1mL subcutaneous injections.
Study: NCT02369198
Drug: TargomiRs
Approvals — FDA: no, EMA: no, PMDA: no
Description: TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.~TargomiRs are IV injected.
Study: NCT03239379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT04198129
Drug: Antibiotic treatment (Unasyn or Cleocin)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial groups will receive a single post-operative dose administration of Unasyn 3g or Clindamycin 600mg (for penicillin allergies)
Study: NCT04198129
Drug: Antibiotic treatment (Augmentin or Cleocin)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients in the trial group will be switched to oral Augmentin 875mg twice a day for 7 days, or oral Clindamycin 150mg to 300mg four times a day for 7 days (for penicillin allergies).
Study: NCT02126293
Drug: Zinc Supplement
Normalized name: Zinc supplement
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03065712
Drug: F-18 Fluoroestradiol
Normalized name: Fluoroestradiol F-18
DrugBank: Fluoroestradiol F-18 (DB15690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F-18 Fluoroestradiol will be administered for PET/CT scan.
Study: NCT06457035
Drug: immunosuppressant
Normalized name: Immunosuppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention was performed in this retrospective cohort study.
Study: NCT03443726
Drug: 4% articaine 1:100.000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articaine in a 4% solution with epinephrine 1:100,000 (Artinibsa; Inibsa Dental, Lliçà de Vall, Spain)
Study: NCT00357526
Drug: OCPs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04263142
Drug: GSK3640254 Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
Study: NCT04263142
Drug: GSK3640254 Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
Study: NCT00824187
Drug: EE20/DRSP(YAZ, BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
Study: NCT00824187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert tablet
Study: NCT00814372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT02294149
Drug: mammalian Omega 3 Fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
Study: NCT02294149
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02712372
Drug: AZD4831
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4831 1-50 mg/g oral suspension
Study: NCT02712372
Drug: AZD4831 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4831 placebo oral suspension
Study: NCT01457118
Drug: NKTR-102 145 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
Study: NCT01457118
Drug: NKTR-102 120 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 90 minute IV infusion of 120 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
Study: NCT01457118
Drug: NKTR-102 95 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 90 minute IV infusion of 95 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
Study: NCT01457118
Drug: NKTR-102 50 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 90 minute IV infusion of 50 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle.
Study: NCT04361643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive a placebo capsule PO daily, days 1, 3 and 5, together with a prophylactic dose of low molecular weight heparin (LMWH) or therapeutic dose if needed due to previous comorbidity.
Study: NCT00433732
Drug: naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00869232
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 day 5-8
Study: NCT04341675
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02191787
Drug: Seresis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02191787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01718509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once-daily, orally, for up to 12 weeks
Study: NCT00882999
Drug: LY2127399
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via Injection
Study: NCT00882999
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via Injection
Study: NCT02293980
Drug: MK-3795
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02576964
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive oral capecitabine, 1000 mg/m\^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
Study: NCT03364608
Drug: AS MDI 90 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS MDI 90 μg (2 actuations of 45 μg/actuation)
Study: NCT01858155
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04556617
Drug: PLX2853
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLX2853 tablets
Study: NCT00258427
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/kg intravenously (IV) on Days -5 through -2.
Study: NCT00365313
Drug: celecoxib, esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01469013
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01469013
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally as background therapy
Study: NCT00862849
Drug: Regular Human Insulin
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00862849
Drug: rHuPH20
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00946946
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
Study: NCT00946946
Drug: Azathioprine placebo
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4g Mesalazine tablets/day AND azathioprine placebo tablets
Study: NCT00525148
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
Study: NCT01614236
Drug: epidural
Normalized name: Epidural 17g 3.5"
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients will be randomized similarly but will undergo surgery under epidural analgesia
Study: NCT02686697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00807846
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 50 mg or 100 mg PO BID for 6 weeks
Study: NCT00807846
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen 7.5 mg/kg PO BID \[maximum of 500 mg BID\] for 6 weeks
Study: NCT02733614
Drug: SRX246
Approvals — FDA: no, EMA: no, PMDA: no
Description: novel V1a receptor antagonist
Study: NCT02733614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT01737112
Drug: 99mTc-3PRGD2
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
Study: NCT04301882
Drug: direct antiviral drugs (DAAs)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with chronic hepatitis C treated with direct antiviral drugs (DAAs)
Study: NCT00908206
Drug: GSK598809
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single 175 mg oral dose of GSK598809.
Study: NCT01638598
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo in each dose level
Study: NCT03302416
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01638598
Drug: Test drug
Normalized name: URINE TEST DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1021958
Study: NCT01769079
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04355156
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * All patients receiving placebo will receive tablets to take BD~* Outpatient monitoring at 2 week intervals for a minimum of 8 weeks, with 2 weekly liver contrast ultrasound for assessment of differential blood supply (CEHPI)
Study: NCT00143221
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03591146
Drug: TLC590
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLC590 lyophilized cake will be reconstituted with the TLC590 reconstitution solution to form the TLC590 ropivacaine liposome injectable suspension
Study: NCT00357253
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
Study: NCT04369430
Drug: AKST4290
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral AKST4290
Study: NCT04369430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo
Study: NCT01251172
Drug: Gamma-Secretase Inhibitor RO4929097
Normalized name: .GAMMA.-OCTALACTONE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT03072121
Drug: SBP placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine \& placebo (for shexiang baoxin pill)
Study: NCT02162485
Drug: Seretide Diskus with charcoal
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03047863
Drug: Cream without rhEGF
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.~Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF
Study: NCT01996306
Drug: CPT-11 (Irinotecan)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
Study: NCT01996306
Drug: l-LV (dl-LV)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
Study: NCT01996306
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
Study: NCT03443843
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet orally
Study: NCT03443843
Drug: Placebo spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Nasal Spray, 2 sprays per nostril
Study: NCT00285298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03374514
Drug: Sterile isotonic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile isotonic saline solution
Study: NCT00305643
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial dose of 750-1500 mg/m\^2 orally twice a day for each 21 day cycle.
Study: NCT00305643
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg given orally twice a day for each 21 day cycle.
Study: NCT00305643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo twice daily on days 1-21
Study: NCT00689819
Drug: Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure (BP) target of \< 140/90 mmHg (or \< 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
Study: NCT00689819
Drug: Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure (BP) target will be \< 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR\< 40 ml/min/1.73 m2: a loop diuretic; eGFR\> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for \> 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
Study: NCT03419767
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients under carotid revascularization surgery taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
Study: NCT02180503
Drug: BI 1356 BS tablet - low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00818324
Drug: OPC-12759 Ophthalmic suspension
Normalized name: Opcon-A Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation,4times/day,for 52weeks
Study: NCT00734773
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
Study: NCT00611897
Drug: N-acetylcysteine and ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (N-acetylcysteine)